Toronto, Ontario, August 4, 2026 — Dr. Aaron Schimmer officially assumes the presidency and scientific directorship of the Ontario Institute for Cancer Research (OICR), beginning a new phase for one of Canada’s major cancer research organizations. His appointment places an internationally recognized hematologist and clinician-scientist at the centre of Ontario’s effort to move discoveries from laboratories into improved cancer prevention, diagnosis and treatment. As President and Scientific Director, Schimmer will guide OICR’s research strategy while advancing its provincial mandate to accelerate cancer research for better health outcomes and a stronger economy.
Schimmer joins OICR after serving as Director of Research at University Health Network’s Princess Margaret Cancer Centre, where he remains a longtime clinician-scientist. His career has focused especially on blood cancers, including leukemia, a group of diseases in which abnormal blood-forming cells multiply uncontrollably and interfere with the production of healthy red blood cells, white blood cells and platelets. Research in this field requires a close connection between molecular biology, clinical medicine and patient care, because the genetic and cellular features of a leukemia can influence how it develops, responds to therapy and eventually becomes resistant to treatment.
With more than 320 peer-reviewed publications and approximately 27,000 citations, Schimmer is one of Canada’s most prominent leukemia researchers. His scientific work has contributed to a broader understanding of the biological mechanisms that drive blood cancers and the challenges involved in developing more effective therapies. In modern oncology, such research often combines genomic analysis, laboratory models, drug testing and clinical investigation to identify vulnerabilities in cancer cells while limiting harm to healthy tissue. This approach is central to precision medicine, which seeks to match treatments to the biological characteristics of an individual patient’s disease.
The new OICR leader also brings extensive experience in the organization and delivery of research. He is a Professor in the University of Toronto’s Departments of Medicine, Medical Biophysics and Institute of Medical Science, and has served as President of the Canadian Hematology Society. He is a Fellow of the Royal Society of Canada. These roles have connected him to researchers, physicians, trainees and health-care institutions across Ontario and nationally, relationships that may help OICR coordinate research programs across disciplines and accelerate collaboration between academic laboratories, hospitals and technology developers.
“After years of close collaboration with OICR, I can attest to the transformative impact the Institute has had on cancer research in Ontario and around the world,” Schimmer said. “I am honoured and humbled to help lead this outstanding organization as we deliver life-changing solutions to the biggest challenges in cancer.” His comments reflect the increasingly collaborative nature of cancer science, where progress often depends not on a single laboratory but on networks that can share data, biological samples, clinical expertise and specialized technologies.
Schimmer takes on the role as OICR launches its Strategic Plan 2026–2031. The plan is intended to shape the institute’s priorities during a period when cancer research is being transformed by advances in genomics, artificial intelligence, imaging, immunology and targeted drug development. These technologies are expanding scientists’ ability to examine tumours at high resolution, track changes over time and distinguish between cancer subtypes that may appear similar under a microscope but behave very differently in the body. Translating these findings into routine care, however, requires rigorous validation, clinical trials, regulatory oversight and equitable access.
Cancer research is now at what Schimmer describes as a watershed moment, with opportunities to improve how cancers are detected, diagnosed and treated. Earlier detection can increase the likelihood that a tumour is found before it spreads, while more precise diagnosis can help physicians select therapies according to a cancer’s molecular profile. Treatment research is also moving beyond conventional approaches that directly kill rapidly dividing cells. New strategies may involve directing the immune system against malignant cells, blocking specific molecular signals or combining therapies to prevent resistant cancer populations from surviving.
For Ontario, the potential benefits extend beyond medicine. OICR is funded by the Government of Ontario and is expected to support research that improves the health of residents while contributing to the province’s life-sciences economy. Cancer research can generate economic activity through biotechnology development, clinical trials, specialized manufacturing, data science and the creation of new diagnostic and therapeutic technologies. The challenge is to ensure that promising discoveries move efficiently through the research pipeline and ultimately become tools that can be used by patients and health-care professionals.
“With world-class research talent, infrastructure and collaborations led by OICR, and the strong support of the Provincial Government, Ontario is poised to lead the next generation of cancer innovations,” Schimmer said. He added that OICR has a unique ability to accelerate cancer research across the province while producing benefits for people living with cancer and for future generations. His leadership will begin as the institute works to implement its new strategic plan and strengthen the connections required to turn scientific ideas into real-world solutions.
“Cancer research is at a watershed moment, full of unprecedented opportunities to transform how cancers are detected, diagnosed and treated,” Schimmer said. “I look forward to working with everyone in the OICR community to write the next chapter for OICR and for cancer research in this province.” The institute’s stated mission is to take on major challenges in cancer research and deliver practical advances that help find cancer earlier and treat it more effectively.
Subject of Research: Cancer research, leukemia, precision medicine and the translation of scientific discoveries into improved cancer detection, diagnosis and treatment.
Article Title: Aaron Schimmer Begins Tenure as President and Scientific Director of Ontario Cancer Research Institute
News Publication Date: August 4, 2026
Keywords: Aaron Schimmer, Ontario Institute for Cancer Research, OICR, leukemia, hematology, cancer research, precision medicine, oncology, cancer innovation, University of Toronto, Princess Margaret Cancer Centre, Strategic Plan 2026–2031
Tags: biomedical research leadershipblood cancer and leukemia researchcancer prevention and treatmentcancer research funding and collaborationcancer research strategyclinical and molecular oncologyhematology and clinician-scientistOntario Cancer Research Institute leadershipOntario health innovationOntario health research initiativesPrincess Margaret Cancer Centretranslational cancer research
